In addition, there are FDA-approved anti-PD-1 antibodies such as nivolumab, pembrolizumab, and dostarlimab for the treatment of different types of cancer, including melanoma, renal cell carcinoma, squamous lung cancer, and metastatic NSCLC [31,32,33]. Here, PDCD1 is linked to cancer.